Product Information
CLONAZEPAM 0.125 MG ODT is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5417 per EA under NDC 00093929067. Its NADAC has been published 213 times since Jun 1, 2022.
Strength
.125 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093929067
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA077194On Market Since
3/2/2022
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 0.125 MG ODT has been published 213 times since Jun 1, 2022, and over the history we have for it it has declined 29.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5417 per EA |
|---|---|
| All-time high | $0.7914 (Jan 10, 2024) |
| All-time low | $0.4221 (Jul 17, 2024) |
| 52-week high | $0.6134 |
| 52-week low | $0.4835 |
| Median price | $0.5423 |
| Average price | $0.5632 |
| Largest weekly change | +47.8% (Aug 21, 2024) |
| Weeks tracked | 213 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Clonazepam market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of CLONAZEPAM 0.125 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 0.125 MG ODT, manufactured by Teva Pharmaceuticals USA Inc., is $0.5417 per EA (NDC 00093929067), effective Jun 24, 2026.
How has the price of CLONAZEPAM 0.125 MG ODT changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 0.125 MG ODT has declined 29.7%. It has been tracked across 213 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 0.125 MG ODT?
Since Jun 1, 2022, the NADAC for CLONAZEPAM 0.125 MG ODT has ranged from a low of $0.4221 (Jul 17, 2024) to a high of $0.7914 (Jan 10, 2024), with a median of $0.5423 per EA.
Are there cheaper alternatives to CLONAZEPAM 0.125 MG ODT?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of CLONAZEPAM 0.125 MG ODT, so no direct lower-cost alternative is listed.
Who manufactures CLONAZEPAM 0.125 MG ODT?
CLONAZEPAM 0.125 MG ODT (NDC 00093929067) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification